News

Novo Nordisk Stock Could Benefit From Eli Lilly’s Weight-Loss Price Hikes

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...

Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
STAT2d

Eli Lilly says it will raise drug prices in Europe to ‘make them lower’ in U.S.

Eli Lilly said it would raise drug prices in Europe to "make them lower" in U.S., though the actual impact on most patients ...

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Lilly’s Zepbound Faces a Potential Weight-Loss Rival. It’s Made by a Chinese Biotech.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

Lilly Signs $1.3 Billion Deal With Superluminal to Discover Obesity Medicines Using AI

(Reuters) -Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...